S
SanegeneBio
Biotech & Life Sciences · Woburn, United States · Founded 2021
Developing targeted RNAi-based medicines for obesity, cardiometabolic and autoimmune diseases MoreLess
SanegeneBio is an emerging biotechnology company specializing in RNA interference (RNAi) therapeutics. The company focuses on developing innovative RNAi-based drugs, particularly for chronic metabolic diseases. SanegeneBio operates in the biopharmaceutical market and serves clients in the healthcare and medical research sectors. The company employs a business model centered on research and development, clinical trials, and strategic collaborations. Revenue is generated through partnerships, licensing agreements, and the commercialization of its proprietary RNAi therapeutics. Notably, SanegeneBio has made significant strides in clinical development, with its first RNAi drug approved for clinical trials in China and ongoing Phase I trials in Australia. The company is headquartered in Suzhou and has recently moved into Phase III of BioBAY, a prominent biopharmaceutical hub. Key personnel include Dr. Jin Yuyan, who leads clinical and non-clinical development, bringing extensive experience from her tenure at Pfizer and Roche. Keywords: RNAi therapeutics, chronic metabolic diseases, clinical trials, biopharmaceutical, drug development, RNA interference, healthcare, medical research, strategic collaborations, innovative drugs.
Company overview
SanegeneBio company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2021
- Headquarters
- Woburn, United States
- Employees
- 32
- Open positions
- 3
- Dealroom signal
- 87.3
Valuation & funding
SanegeneBio funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Dec 2025 | $110M | $440M | Legend Capital · Oriza Holdings · Vivo Capital · TF Capital | ↗ |
| SERIES AOther financing | Dec 2023 | $80M | $500M | TF Capital · Yuansheng BioVenture · TEDA Venture Capital · Xiamen C&D Emerging Industry Equity Investment | ↗ |
Growth signals
SanegeneBio website traffic
Latest recorded traffic for SanegeneBio is 4.6K monthly website visits, up 84% over the last three months. SanegeneBio's team grew 33.3% over the past year.
Hiring
Open positions at SanegeneBio
Current openings linked to this company in Dealroom.
Comparisons
SanegeneBio compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
SanegeneBio's talent
Source: Dealroom Talent Intelligence.
Investors
21 investors on SanegeneBio's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where SanegeneBio has talent and traffic
team presence
In the news
Latest news about SanegeneBio
Recent press, funding announcements, and product moves mentioning SanegeneBio — open to read from the original sources.
Market sentiment
What the market is saying about SanegeneBio
An AI-synthesized read of the highest-engagement posts about SanegeneBio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SanegeneBio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.